Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast Cancer

NCT01112826 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT01112826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01112826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2010
Completion date
December 31, 2019
Enrollment
443 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer